Ticker Details
ACADIA Pharmaceuticals Inc. ACADIA Pharmaceuticals Inc is a biotechnology company which develops and commercializes biopharmaceutical products to address central nervous system disorders. It aims to discover small molecule drugs to address Parkinson's, Alzheimer's and schizophrenia.
IPO Date:	June 1, 2004
Sector:	Healthcare
Industry:	Biotech
Market Cap:	$5.08B
Activated in VL:	True

Average Daily Range
Avg Daily Range:	$0.49 | 2.99%
Avg Daily Range (30 D):	$0.49 | 1.79%
Avg Daily Range (90 D):	$0.43 | 1.78%

Institutional Daily Volume
Avg Daily Volume:	1.22M
Avg Daily Volume (30 D):	1.34M
Avg Daily Volume (90 D):	1.27M

Trade Size
Avg Trade Size (Sh.):	125
Avg Trade Size (Sh.) (30 D):	64
Avg Trade Size (Sh.) (90 D):	61

Institutional Trades
Total Institutional Trades:	10,538
Avg Institutional Trade:	$2.37M
Avg Institutional Trade (30 D):	$2.76M
Avg Institutional Trade (90 D):	$3.69M
Avg Institutional Trade Volume:	.1M
Avg Institutional Trades (Per Day):	3

Market Closing Trades
Avg Closing Trade:	$4.38M
Avg Closing Trade (30 D):	$7.31M
Avg Closing Trade (90 D):	$8.06M
Avg Closing Volume:	182.34K

News

Jun 26, 2026 @ 4:17 PM Why Acadia Pharmaceuticals Stock Is Soaring Today Source: James Brumley

Dec 4, 2025 @ 12:12 AM Acadia Stock Up 59% in a Year — Is a $51 Mi... Source: Jonathan Ponciano

Sep 11, 2025 @ 3:30 AM Questex’s Fierce Pharma Announces the 2025 ... Source: Linda Lam

Apr 22, 2025 @ 5:00 PM Parkinson’s Disease Therapeutic Domain Proj... Source: Delveinsight

Feb 11, 2025 @ 8:48 AM Neuroregeneration Therapy Market to Surpass USD 64... Source: Transparency Market Research

Financials
	TTM	Q2 2026	Q1 2026
Basic EPS	$2.25	$.18	$.02
Diluted EPS	$2.23	$.18	$.02
Revenue	$1.14B	$307.96M	$268.06M
Gross Profit	$1.04B	$279.64M	$243.27M
Net Income / Loss	$380.48M	$31.5M	$3.64M
Operating Income / Loss	$86.37M	$37.84M	$-4.62M
Cost of Revenue	$100.98M	$28.32M	$24.79M
Net Cash Flow	$129.66M	$102.75M	$104.49M
PE Ratio